NCT02796898View on ClinicalTrials.gov

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions
Prostate CancerRising Prostate Specific Antigen (PSA)
Interventions
DRUG

SM88 (Cohort 1)

"* Tyrosine Isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"

DRUG

SM88 (Cohort 2)

"* Tyrosine Isomers - 460 mg (230 mg bid)~* Phenytoin - 50 mg qd~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"

Trial Locations (5)

10461

Montefiore Medical Center- Montefiore Medical Park, The Bronx

10469

Eastchester Center for Cancer Care, The Bronx

19004

MidLantic Urology, Bala-Cynwyd

08648

AdvanceMed Research, Lawrence

11530-1664

AccuMed Research Associates, Garden City

All Listed Sponsors
lead

Tyme, Inc

INDUSTRY

NCT02796898 - Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter